Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Status:
Withdrawn
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label phase I study in which dovitinib is given in combination with
bortezomib and dexamethasone. Dovitinib dose escalation is planned in order to determine its
maximum tolerated dose when given in this combination.